Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Astugenal Clear all

Conditions: Malignant Brain Tumors
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood CNS Primitive Neuroectodermal Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ependymoma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1966 – 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Meningioma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low-Grade Astrocytoma, Nos
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme of the Brain
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Adrenocortical Carcinoma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Soft Tissue Sarcoma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Liver Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 14 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1977 – 1999
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mixed Gliomas
Interventions: Atengenal, Astugenal; Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bronchial Alveolar; Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenocarcinoma of the Esophagus
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Lung Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Small Intestine Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primitive Neuroectodermal Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Grade Glioma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oligodendroglioma, Adult
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Bladder Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Mesothelioma
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 1 Year to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Kidney Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Brain Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 6 Months to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage IV Prostate Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1997
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Brain Tumor
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors

Antineoplaston Therapy in Treating Patients With Ependymoma

Antineoplaston Therapy in Treating Patients With Meningioma

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer

Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma